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miR-433-3p Negatively Regulates Bone Formation and Targets Critical for
Osteoblast Function
John Garcia, MPH, MSc
University of Connecticut, 2020

Osteoblastic differentiation is tightly controlled by multiple signaling pathways
associated with key transcription factors, as well as a number of microRNAs (miRNAs). miRNAs
are small noncoding RNAs that function in the post-transcriptional regulation of gene
expression. While clinical strategies to combat the reduction in bone density have often
centered on impeding further bone resorption, this strategy neglects to promote bone
formation, a component which is particularly problematic in the aging population. miRNAs
could serve to bridge that gap, as potential therapeutic candidates. Several studies have
established that miRNAs can direct osteoprogenitors towards an osteoblastic lineage through
modulation of Wnt, MAPK, TGFβ and BMP signaling. Thus, this thesis consists of 2 independent
manuscripts. First, a primary research article details novel mechanisms by which one particular
miRNA, miR-433-3p, regulates osteoblastic differentiation via modulation of Wnt, MAPK, PTH
and glucocorticoid signaling. Second, a comprehensive review documents how miRNAs regulate
TGFβ and BMP signaling to promote or repress osteoblast formation and function.
Regarding miR-433-3p, this miRNA can specifically target Runx2 and is repressed by
BMP2 signaling. Herein, we demonstrate that miR-433-3p is progressively decreased during
osteoblastic differentiation of primary mouse bone marrow stromal cells in vitro, and we
confirm its negative regulation of this process. Although repressors of osteoblastic
differentiation often promote adipogenesis, inhibition of miR-433-3p did not affect adipocyte
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differentiation in vitro. Additionally, since multiple pathways regulate osteogenesis, using 3'
UTR-Luciferase reporter assays five novel miR-433 targets involved in PTH, MAPK, Wnt, and
glucocorticoid signaling pathways were validated.
In vivo, expression of a miR-433-3p inhibitor or tough decoy in the osteoblastic lineage
increased trabecular bone volume. Mice expressing the miR-433 tough decoy displayed
increased bone formation without alterations in osteoblast or osteoclast numbers or surface,
indicating an impact on osteoblast activity. Overall, we demonstrated that miR-433 is a negative
regulator of bone formation in vivo, targeting key bone-anabolic pathways including those
involved in PTH signaling, MAPK, Wnt and endogenous glucocorticoids. Local delivery of miR433 inhibitor could present a strategy for the management of bone loss disorders and bone
defect repair.
Having a wide understanding of the signaling pathways, differentiating factors, and the
mechanisms necessary for the miRNA-mediated induction of multipotent cells along an
osteoblastic lineage is key for the effective utilization of miRNAs as therapeutic candidates in
the management of bone disorders. Thus, this thesis also contains a review that showcases
miRNAs regulating TGFβ and BMP signaling pathways in bone forming osteoblasts, to illustrate
their interaction with and impact on bone formation. BMP signaling is particularly relevant to
bone defect repair, as localized delivery of osteogenic BMPs is presently used in the clinic.
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Chapter 1
Introduction
The goal of the work presented in this thesis is to illustrate the central role of microRNAs in
the control of bone-forming osteoblasts and to disseminate novel observations on the function
of one miRNA, miR-433, in the osteoblast lineage.

Osteoblasts are terminally differentiated cells with mesenchymal origins, known to
possess pivotal roles in sustaining bone microstructure and homeostasis 1. These bone forming
cells, with the ability to synthesize and secrete bone matrix proteins, are implicated in the
pathophysiology of various bone disorders, especially osteoporosis 1. Osteoblasts originate
from mesenchymal stem cells (MSCs), which are non-hematopoietic multipotent cells within
bone marrow. Bone marrow-derived MSCs (BMSCs) are capable of differentiating into multiple
cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes and have been applied
medically for diverse indications ranging from bone regeneration to cardiac repair

2.

Differentiation of MSCs into osteoblasts is carefully controlled by transcription factors such as
Runx2, and signaling pathways such as BMP, TGF, and Wnt 1.

Multiple studies have shown that miRNAs can direct mesenchymal stem cells (MCSs)
towards an osteoblastic lineage through modulation of Wnt, TGFβ and BMP signaling 3. miRNAs
are small non-coding RNAs that function in the post-transcriptional regulation of gene
expression and are involved in many biological processes such as self-renewal, proliferation,
function, and differentiation

4,5,6,7,8.

miRNAs exert their regulatory role through direct

interaction with mRNAs that contain sequences complementary to the miRNA
1

4,5,6,7,8.

miRNAs

interacting with their target mRNA regulate gene expression through the inhibition of
translation and/or enhancement of mRNA degradation

4,5,6,7,8.

In the mesenchymal lineage,

miRNAs can promote or inhibit differentiation toward the osteoblastic fate through modulation
of signaling pathways important in bone formation 4,5,6,7,8.

Chapter 2 of this thesis is a primary research article in which we describe new data on the
function of miR-433 in osteoblast lineage, including its ability to regulate signaling pathways
that converge on bone formation. We demonstrate that miR-433-3p is progressively decreased
during osteoblastic differentiation of primary mouse BMSCs in vitro, and we confirm its
negative regulation of this process. Additionally, since multiple pathways regulate osteogenesis,
we identify and validate five novel miR-433 targets involved in PTH, MAPK, Wnt and
glucocorticoid signaling.

Chapter 3 of this thesis is a comprehensive review article highlighting components of the
TGF/BMP signaling family and their regulation by specific miRNAs. The TGF/BMP signaling
pathway is particularly relevant to bone health and therapeutics because members of this
superfamily are implicated in the function and metabolism of bone cells 9. The role of TGF in
osteoblasts is context dependent. It can exert a biphasic effect on osteoblastic differentiation
by promoting activation, proliferation, and early commitment of pre-osteoblasts at an early
state, while impeding terminal osteoblast differentiation at later stages, especially during
mineralization

10,11.

BMPs, another member of the TGFβ superfamily, play a key role in bone

2

formation due to their strong osteogenic capacities and can promote the restoration of criticalsize bone defects 12,13. Use of miRNA based therapeutics is also discussed.

Overall, by deepening our understanding of the mechanisms that regulate TGFβ/BMP
signaling, we can develop appropriate therapeutic strategies aimed at treating skeletal
pathologies. Having a wide knowledge of the signaling pathways, differentiation factors, and
mechanisms necessary for the miRNA-mediated induction of multipotent cells along an
osteoblastic lineage is critical for the effective utilization of miRNAs as therapeutic candidates in
the management of bone disorders.

3

Chapter 2
miR-433-3p Suppresses Bone Formation and mRNAs that are Critical for Osteoblast Function
Abstract
microRNAs (miRNAs) are key post-transcriptional regulators of osteoblastic commitment
and differentiation. miR-433-3p can target Runx2 and is repressed by BMP2 signaling. Here, we
demonstrate that miR-433-3p is progressively decreased during osteoblastic differentiation of
primary mouse bone marrow stromal cells in vitro, and we confirm its negative regulation of
this process. Although repressors of osteoblastic differentiation often promote adipogenesis,
inhibition of miR-433-3p did not affect adipocyte differentiation in vitro.
Multiple pathways regulate osteogenesis. Using 3' UTR-Luciferase reporter assays, five
novel miR-433 targets involved in PTH, MAPK, Wnt, and glucocorticoid signaling pathways were
validated. We demonstrate that CREB1 is a miR-433 target, and this transcription factor
mediates key signaling downstream of PTH receptor activation. We also show that miR-433-3p
targets HSD11B1, the enzyme that locally converts inactive glucocorticoids to their active form.
miR-433-3p dampens glucocorticoid signaling, and targeting of HSD11B1 could contribute to
this phenomenon. Moreover, miR-433 targets RSPO3, a LGR ligand that enhances Wnt
signaling. Notably, canonical Wnt signaling is also blunted by miR-433 activity. In the MAPK
signaling pathway, p38a/MAPK14 and its upstream kinase MKK3/MAP2K3 are miR-433-3p
targets, whereas JNK1 is not. P38 MAPK signaling promotes osteogenesis; it is activated by
BMP2 and it also integrates signals from Wnt and PTH receptor activation.
In vivo, expression of a miR-433-3p inhibitor or tough decoy in the osteoblastic lineage
increased trabecular bone volume. Mice expressing the miR-433 tough decoy displayed
increased bone formation without alterations in osteoblast or osteoclast numbers or surface,
4

indicating an impact on osteoblast activity. Overall, we demonstrated that miR-433 is a negative
regulator of bone formation in vivo, targeting key bone-anabolic pathways including those
involved in PTH signaling, MAPK, Wnt and endogenous glucocorticoids. Local delivery of a miR433 inhibitor could present a strategy for the management of bone loss disorders and bone
defect repair.

Introduction
Bone undergoes continuous cycles of remodeling necessary to maintain its structural
integrity, adapt to mechanical use, meet metabolic demands, and facilitate fracture repair
1,14,15,16.

The ongoing remodeling cycle is orchestrated by bone-resorptive osteoclasts, bone-

forming osteoblasts, and osteocytes that act as mechano-sensors imbedded in the bone

1,14,15.

An imbalance between bone formation and resorption can compromise bone mass and quality
14,15,16.

The gene expression programs that regulate bone formation and resorption are

informed by cell-to-cell communication between native bone cells, as well as signals from
growth factors, cytokines, and hormones

4,5,6,7,14,15.

These signals regulate gene expression at

multiple levels, utilizing transcriptional, post-transcriptional and post-translational mechanisms.
In the last decade, microRNA (miRNA)-mediated mechanisms have emerged as central to the
regulation of bone resorption and formation 1,4,16,17,18.

miRNAs are small noncoding RNAs that function in the post-transcriptional regulation of
gene expression

4,5,6,7,8.

miRNAs exert their regulatory role through direct interaction with

mRNAs that contain sequences complementary to the miRNA

5

4,5,6,7,8.

When loaded into the

RNA-induced silencing complex (RISC), miRNAs act as a “guiding strand” to recruit the RISC to
complementary regions within the target mRNAs

5,6,7,8,19.

miRNAs interacting with their target

mRNAs regulate gene expression through the inhibition of translation and/or enhancement of
mRNA degradation

4,5,6,7,8.

These 21-24 base RNAs are involved in many biological processes

such as self-renewal, proliferation, function, and differentiation

4,5,6,7

. In the mesenchymal

lineage, miRNAs can promote or inhibit differentiation toward the osteoblastic fate through
modulation of signaling pathways important in bone formation, including the Wnt, TGFβ and
BMP pathways

4,5,6,7,8.

A single miRNA can potentially target many distinct mRNAs. Frequently,

miRNAs target multiple mRNAs involved in the same or a correlated pathway, to modify the
tempo and amplitude of signaling programs, making them excellent therapeutic targets.

Although the impact of some miRNAs on the skeleton is well documented, other miRNAs,
such as miR-433, are less well understood. miR-433-3p is expressed in the osteoblast lineage,
but not in osteoclasts 20. We initially found that miR-433-3p could differentially target a single
nucleotide polymorphism (SNP) in human osteonectin (SPARC), an abundant non-collagenous
bone matrix protein that regulates osteoblast differentiation and survival

21,22.

Osteonectin

plays a key role in maintenance of bone mass, and this osteonectin 3’ UTR SNP, that mediated
differential binding of miR-433-3p, was associated with in bone density in a cohort of Caucasian
men with idiopathic osteoporosis

21,22.

A novel set of human osteonectin 3’ UTR knock-in mice

validated that this SNP regulates bone volume and the anabolic bone response to intermittent
parathyroid hormone (PTH) administration 22.

6

Additional evidence for a prominent role for miR-433 in skeletal biology comes from
another SNP study, in which a nucleotide substitution in the 3’ UTR of histone deacetylase 6
(HDAC6) negates post-transcriptional regulation by miR-433. This results in the overexpression
of the HDAC6 protein in a novel form of dominant X-linked human chondrodysplasia, and marks
one of the first examples of a skeletal disease caused by a dysregulation of miRNA-mediated
regulation of mRNAs 23,24. In vitro studies in osteoblastic cells have validated additional miR-433
targets important for bone formation, including Runx2 25,26. miR-433 can also target Hif1α and
Igf1, genes responsible for the coupling of angiogenic and osteogenic activity needed for bone
formation and osteoblast proliferation, and the enhancement osteoblast differentiation 26.

The miR-433 locus is located within the Glt2-Dio3 miRNA mega-cluster on human
chromosome 14, a genomic locus that is conserved on mouse chromosome 12. The miR-433
gene structure and transcriptional regulation are highly conserved across mammalian species
suggesting that it may exert similar regulatory effects

27,28,29,30.

miR-433 is located within the

anti-retrotransposon-like 1 (RTL1) transcript, which negatively regulates RTL1, a protein coding
gene that plays an important role in placenta development

31.

While mutations and deletions

within the human 14q32.2 imprinted region, which contains the miR-433 locus, are associated
with impaired growth as well as facial and thoracic abnormalities, the contribution of miR-433
to this phenotype is unclear 32.

We sought to better understand the role of miR-433-3p in osteoblastic lineage commitment
in vitro and bone formation in vivo. Herein, we show that, using C3H10T1/2 mesenchymal cells
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stably transduced with a miR-433-3p “tough decoy” (TuD) to suppress endogenous miR-433-3p
activity, miR-433 is a negative regulator of osteoblastic differentiation, but does not impact
adipogenesis. Further, we validated novel miR-433-3p targets in multiple pathways playing an
important role in osteoblastogenesis and bone formation, revealing potential mechanisms by
which miR-433 functions as a negative regulator of these processes. Lastly, using mice
expressing a miR-433TuD in osteogenic cells, we show that this miRNA decreases osteoblastic
activity and that its inhibition promotes bone formation.

Methods
Animal Care
We previously described a line of C57BL/6 mice expressing a transgene cassette in which
a 3.6-kb fragment of the rat Col1A1 promoter and 1.6 kb of the first intron drives expression of
the tdTomato reporter gene containing miR-433TuDs within its 3’-UTR

33,34.

The sequence for

the miR-433 transgene TuD cassette is reported in Supplemental Table 1. Wild type and miR433TuD littermates were housed under specific pathogen-free conditions within the Center for
Comparative Medicine at UConn Health. Only male mice were used for these studies. All mice
were kept under a 12-h light/dark cycle and were provided with standard chow and water ad
libitum. All animal protocols were reviewed and approved by the Institutional Animal Care and
Use Committee (IACUC) at UConn Health.

Cell Culture

8

A multipotent mouse mesenchymal cell line, C3H10T1/2 clone 8, was obtained from the
American Type Culture Collection (ATCC® CCL-226™, Manassas, VA) and cultured in DMEM
(Gibco Life Technologies, Carlsbad, CA), 10% heat-inactivated Fetal Bovine Serum (FBS, Lonza,
Basel, Switzerland), and 1% Penicillin/Streptomycin. Primary bone marrow stromal cells
(BMSCs) from 8 week old male C57Bl/6 mice were isolated from tibias and femurs by
centrifugation and cultured in αMEM (Gibco Life Technologies), 10% heat-inactivated FBS, and
1% Penicillin/Streptomycin 35.

Osteogenic Differentiation
Osteogenic differentiation of C3H10T1/2 cells was induced by culture in DMEM, 10%
heat-inactivated FBS, 1% Penicillin/Streptomycin, 100 μg/ml Ascorbic Acid (Sigma-Aldrich, St.
Louis, MO), 2 μM Purmorphamine (Sigma-Aldrich), 8 mM β-glycerophosphate (Sigma-Aldrich),
and 50 ng/ml BMP2 (gift from Medtronic, Dublin, Ireland). Once primary BMSCs reached
confluence,

they

were

cultured

in

αMEM,

10%

heat-inactivated

FBS,

1%

Penicillin/Streptomycin, 50 μg/ml Ascorbic Acid, and 5 mM β-glycerophosphate.
Mineral deposition was measured by staining cultures with 1% alizarin red S (SigmaAldrich). Stain was then extracted and quantified by at absorbance 405 nm

22.

Cultures were

also stained for alkaline phosphatase activity using an Alkaline Phosphatase kit (#86R, SigmaAldrich), according to the manufacturer’s instructions.

Adipogenic Differentiation

9

Adipogenic differentiation was achieved using αMEM media supplemented with 10%
FBS, 500 nM rosiglitazone (Sigma-Aldrich) and 1 μM insulin (Sigma-Aldrich). Cells were then
stained with 0.5% Oil Red O solution to visualize fat droplets.

Generation of an Inducible miR-433 Tough Decoy Model
To knockdown activity of miR-433 in vitro, C3H10T1/2 cells were stably transduced with
a lentiviral vector (pSLIK) in which a doxycycline (Dox)-inducible promoter drives expression of
construct expressing either a miR-433 TuD (containing complementary miR-433 binding sites)
or a non-targeting TuD (containing C. elegans miR-67 binding sites)

26.

Pools of stably

transduced cells were selected for hygromycin resistance. The sequence for the miR-433 and
non-targeting TuD is reported in Supplemental Table 1. The single lentivector for inducible
knockdown (pSLIK) contains a ubiquitin C promoter which drives constitutive expression of
reverse Tet transactivator (rtTA3) (Addgene, Cambridge, MA)

36.

Doxycycline (Dox) treatment

stimulates the rtTA to drive transcription of TRE, allowing for inducible expression of the TuD.
Once expressed, the miR-433TuD acts as an inhibitor for endogenous miR-433 activity. The 1
µg/ml dose of Dox used in these studies was previously shown to maximally induce expression
of the decoy construct 26.

Static and Dynamic Histomorphometry
For dynamic histomorphometry, mice were injected with Alizarin-3-methyliminodiacetic
acid (30 mg/kg; Sigma-Aldrich) and Calcein (10 mg/kg; Sigma-Aldrich) 10 and 3 days prior to
euthanasia, respectively. Post-harvest, femurs were fixed for 7 days in 4% paraformaldehyde at
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4°C. After fixation, femurs were placed in 30% sucrose for 24-36 hours, embedded in O.C.T.
(Thermofisher, Waltham, MA) and flash frozen in 2-methylbutane (Fisher, Hampton, NH). 7 μm
sections were collected using a Leica cryostat and a Cryofilm II tape transfer system (Section
Lab Co. Ltd., Hiroshima, Japan), and cross-linked to glass slides using Norland Optical Adhesive.
For static histomorphometry, femurs were fixed 7 days in 4% paraformaldehyde at 4°C. After
fixation, femurs were decalcified for 21 days in a 14% EDTA and 2.7% NH 4OH. Femurs were
then dehydrated, embedded in paraffin, and sectioned using a Leica microtome. 7 μm sections
were stained for Tartrate-resistant Acid Phosphatase (TRAP) activity, stain to visualize
osteoclasts, and counterstained with hematoxylin. Dynamic and static histomorphometry
parameters were quantified using Osteomeasure software (OsteoMetrics), measuring 200 μm
from the growth plate and cortical bone, as advised by the Nomenclature Committee of the
American Society for Bone and Mineral Research 37. All samples were blinded prior to analysis.

microCT
Femurs from miR-433TuD mice and wild type controls were fixed in 70% ethanol at 4°C
until imaging. The distal region of the femur was analyzed at 8 μm voxel resolution using microCT (UConn Health microCT Core: μCT40, Scanco Medical AG, Wangen-Brüttisellen, Switzerland)
to quantify trabecular and cortical morphometry 38. Samples were blinded prior to analysis.

RNA Extraction and qPCR
RNA was extracted from cell cultures using TRIzol Reagent (Life Technologies, Carlsbad,
CA). Total RNA was quantified, treated with RQ1 DNase (Promega, Madison, WI), and subjected
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to random hexamer-primed reverse transcription using Moloney murine leukemia virus-reverse
transcriptase (Invitrogen, Carlsbad, CA). Gene expression was quantified by qPCR with iQ SYBR
Green Supermix (Bio-Rad) and normalized to 18S rRNA levels.
miRNA levels were analyzed using TaqMan MicroRNA Assays (Life Technologies,
Carlsbad, CA). RNA was reverse transcribed using mature miRNA-specific primers to generate
cDNA and microRNA expression was quantified by qPCR and normalized to snoRNA 202 levels.
In vitro studies were performed at 2-3 times and each experiment contained at least 4
biological replicates, all assayed in duplicate.

Luciferase Constructs
Using gene-specific PCR primers, the 3’ UTR of MKK3 (cDNA bases 1214-2142), p38
(cDNA bases1527-3570), RSPO3 (cDNA bases 1370-2350), JNK1 (cDNA bases 3570-4480), CREB1
(cDNA bases 1211-2160 and 4826-5873), and Hsd11β1 (cDNA bases 943-1292) were amplified
from mouse genomic DNA. Primer sequences are reported in Supplemental Table 2. Using
specific restriction enzymes, the amplified fragments were cloned into the multicloning site of
the pMIR REPORT Luciferase plasmid (Ambion, Austin, TX), in which a Cytomegalovirus (CMV)
promoter drives expression of the Luciferase reporter. All constructs were verified by Sanger
sequencing (GeneWiz, South Plainfield, NJ).

Luciferase Assays
C3H10T1/2 cells were plated at 15,000 cells/cm 2. After 24 hours, cells were cotransfected with the Luciferase constructs containing the 3’ UTR of target mRNA, a
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constitutively expressing β-Galactosidase construct that serves as a control for transfection
efficiency (GenBank accession number U02451) (Clontech, Mountain View, CA), and 80 nM
mirVana™ anti-miR-433-3p or a mirVana™ negative control #1 (non-targeting) miRNA hairpin
inhibitors (Ambion). Transient transfection was accomplished using BioT transfection reagent
(1.5μl:1μg BioT:nucleic acid; Bioland Scientific, Paramount, CA), according to the
manufacturer’s instructions. 24 hours post-transfection, growth medium was renewed. After 24
hours recovery, cells were serum deprived overnight prior to harvest using a Reporter Lysis
Buffer (Promega, Madison, WI). To examine canonical Wnt signaling, cells were co-transfected
with miRNA inhibitors and a TOPFlash plasmid (M50 Super 8x TOPFlash Plasmid #12456;
Addgene). After recovery, cells were serum-deprived overnight prior to treatment with 30-50
ng/ml recombinant human Wnt-3a (R&D Systems Minneapolis, MN) or vehicle for 6 hours
before harvest. Samples were analyzed for Luciferase activity using a Luciferase Assay System
(Promega) and normalized to β-Galactosidase activity using Galacton® (Applied Biosystems,
Foster City, CA). Each Luciferase experiment was performed at least 4 times using 6 biological
replicates.

Statistics
Data presented in bar graphs are mean ± standard deviation, with n ≥ 3, as listed in the
figure legends. For data presented as box-and-whisker plots, the top and bottom of each box
represent the 75% and 25% quartiles, respectively, whereas the middle line represents the
mean. The whiskers denote the minimum and maximum of the data set, and the open circles or
“x” represent individual outliers. Statistical significance was determined using a Student’s t test
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or a two tailed ANOVA with Bonferroni post-hoc test, as appropriate (KaleidaGraph, Synergy
Software, Reading, PA).

Results
miR-433 Decreases During Osteogenic Differentiation
In C3H10T1/2 cells, miR-433 was suggested to be a negative regulator of osteoblast
differentiation 25. However, the expression of miR-433 during osteogenesis in primary cells has

Figure 2.1 miR-433 decreases during osteogenic differentiation of bone marrow stromal cells
Bone marrow stromal cells were differentiated with β-glycerophosphate and ascorbic acid for
up to 4 weeks. (A) Alkaline phosphatase (Ap), Runx2, and osteocalcin (Oc) mRNA expression.
(B) Alkaline phosphatase (AP) and Alizarin Red S staining. (C) miR-433-3p expression.
* = significantly different from day 0, p < 0.05. (n=8) Data produced by Spenser Smith
not been examined. Therefore, primary BMSCs were cultured in an osteogenic cocktail for up to
4 weeks. When comparing to confluence, expression of osteogenic markers genes alkaline
phosphatase (AP; early marker for osteoblast differentiation), Runt-related transcriptional
factors 2 (Runx2; key transcription master associated with osteoblasts), and osteocalcin (Oc;
Bglap; terminal osteoblast differentiation marker) was increased during differentiation (Figure

14

Figure 2.2. miR-433 decoy enhances osteogenic differentiation in vitro
C3H10T1/2 cells were stably transduced with a Dox-inducible construct carrying either a nontargeting or miR-433 decoy in the 3’ UTR of the reporter gene GFP. The miR-433-3p binding
sites are denoted in red (A). Non-targeting and miR-433 decoy cells were cultured with BMP2
for up to 3 weeks, in the absence or presence of 1 µg/ml Dox. Alkaline phosphatase (Ap)
mRNA expression in (B) non-targeting and (E) miR-433 decoy cells. Runx2 mRNA expression in
(C) non-targeting and (F) miR-433 decoy cells. Osteocalcin mRNA expression in (D) nontargeting and (G) miR-433 decoy cells. # = significantly different from day 0, p < 0.05. * =
significantly different from corresponding no Dox control, p < 0.05. (n=8)
Data produced by Spenser Smith
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2.1A). Alkaline phosphatase activity and mineralized matrix deposition were also substantially
increased, as indicated by alkaline phosphatase and Alizarin Red S staining respectively (Figure
2.1B). Contrary to osteogenic markers genes, miR-433 expression was progressively decreased
during osteogenic differentiation, with a 70% reduction noted at week 3 (Figure 2.1C).

miR-433 Negatively Regulates Osteoblastic Differentiation in vitro
To determine whether miR-433 impacts osteogenic differentiation, we used a previously
described stably transduced C3H10T1/2 cell line expressing a Doxycycline (Dox) inducible miR433TuD 26,36 (Figure 2.2A). The TuD acts as an inhibitor for endogenous miR-433 and its activity
phenocopies that of a transiently transfected miR-433-3p inhibitor, in regard to its ability to
relieve repression of miR-433 on its targets 26.

To induce osteogenic differentiation, the stably transduced non-targeting miRNA TuD
(control) or miR-433TuD C3H10T1/2 cells were cultured for up to 3 weeks in an osteogenic
cocktail containing 50 ng/ml bone morphogenetic protein 2 (BMP2). In cells expressing the nontargeting decoy, osteogenic marker genes alkaline phosphatase, Runx2, and osteocalcin were
increased at all time points and were not altered by the presence of Dox (Figure 2.2B,C,D). In
the absence of Dox, osteogenic gene expression in the miR-433TuD cells was similar to that of
the non-targeting controls. However, upon treatment with Dox, there was a significant
enhancement in the expression of osteogenic marker genes alkaline phosphatase, Runx2, and
osteocalcin (Figure 2.2E,F,G). Growth curves for the non-targeting and miR-433TuD cells
cultured in the presence or absence of Dox were superimposable, suggesting that enhanced cell

16

number did not play a role in the impact of miR-433 inhibition on osteoblastogenesis in vitro
(data not shown). Overall, miR-433 acts as a negative regulator of osteogenesis in vitro.

miR-433 Does Not Alter Adipogenic Differentiation in vitro
Since osteoblasts and adipocytes can arise from a common progenitor within the bone
marrow and marrow adipogenesis is often inversely correlated with bone mass, we examined
the role of miR-433 in adipogenic differentiation

39.

Primary BMSC cultures were stimulated

with an adipogenic cocktail containing rosiglitazone and insulin for up to 9 days and mRNA
levels for adipogenic differentiation markers Cebpα (CCAAT/enhancer binding protein α), Pparγ
(peroxisome proliferator activated receptor γ), and Fabp4 (fatty acid binding protein 4) were
examined. Adipogenic marker genes were higher at all time points compared to day 0 (Figure
2.3A). Oil red O staining showed increasing lipid droplet accumulation throughout the 9 days of
differentiation (Figure 2.3C). However, miR-433 expression was not significantly altered over
the course of adipogenic differentiation in BMSCs (Figure 2.3B).

Although miR-433 expression did not change during adipogenesis, it could still exert a
regulatory role on adipogenic differentiation. To examine this, non-targeting and miR-433TuD
cells were cultured with the adipogenic cocktail, in the absence or presence of Dox. In nontargeting TuD cells, Cebpα and Pparγ mRNA expression were induced, but they were not
altered by treatment with Dox (Figure 2.3D, E). Similarly, in miR-433TuD cells, the expression of
adipogenic marker genes was not altered in the presence or absence of Dox (Figure 2.3F, G),
suggesting that miR-433 does not regulate adipogenic differentiation in vitro.
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Figure 2.3. miR-433 is not altered during adipogenic differentiation of bone marrow stromal
cells
Primary BMSCs were differentiated with rosiglitazone and insulin for up to 9 days. (A) Cebpα,
Pparγ, and Fabp4 mRNA expression. (B) miR-433 expression. (C) Oil Red O staining. Non-targeting
and miR-433 decoy cells were differentiated in the absence of presence of 1 µg/ml Dox. Cebpα
mRNA expression in (D) nontargeting and (F) miR-433 decoy cells. Pparγ mRNA expression in (E)
non-targeting and (G) miR-433 decoy cells. # = significantly different from day 0, p < 0.05. (n=8)
Data produced by Spenser Smith
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miR-433 Targets in the Osteoblast Lineage
Runx2 is critical for osteoblastic differentiation and was previously shown to be a miR433 target 25. However, each miRNA can potentially target hundreds of miRNAs. Therefore, we
sought to validate other miR-433-3p targets that may have an impact on osteoblast function.
We used an in silico approach (miRanda, TargetScan, RNAhybrid) to identify potential novel
targets within pathways important for osteoblasts, and our analysis suggested that genes active
in PTH, glucocorticoid, MAPK (Mitogen-activated Protein Kinase) and Wnt signaling pathways
could be potential miR-433 targets (Figure 2.4A).

PTH acts in the osteoblastic lineage to promote bone formation, as well as bone
resorption 40,41. Creb1 (cAMP Responsive Element Binding Protein 1) is a key transcription factor
mediating major effects of PTH signaling on gene expression in osteoblasts

40,41.

Whereas

several studies in humans demonstrated that Creb1 is targeted by miR-433, it is not yet known
whether this regulatory action is conserved in mice 42,43,44. Our bioinformatic analysis revealed
two potential miR-433 binding sites in the Creb1 3’ UTR. Therefore, both proximal and a distal
Luciferase-Creb1 3’ UTR constructs were created in the pMIR-REPORT reporter plasmid, to test
binding site function (Figure 2.4A). C3H10T1/2 cells were transiently co-transfected reporter
plasmids along with either a non-targeting or miR-433 inhibitor. Co-transfection with the miR433 inhibitor relieved repression of both proximal and distal Luciferase-Creb1 3’ UTR
constructs, demonstrating independent miR-433-responsive regulatory regions in the Creb1 3’
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UTR and also establishing that this regulatory mechanism active in humans is conserved in mice
(Figure 2.4B).

We recently showed that miR-433 dampens glucocorticoid receptor signaling, and our
bioinformatics analysis suggested that Hsd11β1 (11β-hydroxysteroid dehydrogenase 1) (Figure
2.4A), the enzyme that allows cells to locally convert inactive glucocorticoids to their active
form, could be a miR-433 target

26,45,46,47

. Therefore, we created an Hsd11β1 3’ UTR reporter

plasmid, which was co-transfected into C3H10T1/2 cells with either a non-targeting or miR-433
inhibitor. miR-433 inhibition resulted in a significant increase in luciferase activity, validating
Hsd11β1 as a novel miR-433 target (Figure 2.4C).
MAPKs play a critical role in transducing extracellular signals to intracellular effectors.
The response of osteoblasts to PTH, TGFβ, BMP2, and Wnt ligands requires the activity of
MAPKs 48,49,50,51,53,54. MAPKs are particularly well studied in bone and have a positive impact on
osteoblast differentiation and function

55.

Bioinformatic analysis suggested that several

components of the MAPK signaling pathway could be directly targeted by miR-433-3p, including
MKK3 (Mitogen-activated Protein Kinase Kinase 3), p38 (Mitogen-activated Protein Kinase 14)
and JNK1 (Mitogen-activated Protein Kinase 8) (Figure 2.4A)

56,57,58,59.

To determine whether

miR-433 targets these murine RNAs, 3’ UTR luciferase reporter constructs were created and
transfected into C3H10T1/2 cells with non-targeting or miR-433 inhibitor, and luciferase activity
was quantified. Whereas miR-433 inhibition did not affect the luciferase activity of the JNK1 3’
UTR construct, it did relieve repression of the p38 3’UTR and that of MKK3, the upstream
kinase responsible to activating p38  (Figure 2.4D-F).
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Figure 2.4. miR-433 targets glucocorticoid, MAPK and canonical Wnt signaling pathways
(A) Interaction of miR-433-3p with potential targets as predicted by RNAhybrid. Activity of the (B) CREB1, (C)
Hsd11β1, (D) JNK1, (E) MKK3, (F) p38α, and (G) RSPO3 luciferase-3’ UTR reporter constructs in transiently
transfected C3H10T1/2 cells, in the presence of miR-433 or non-targeting miRNA inhibitor. (H) Activity of the
Wnt responsive TopFLASH luciferase reporter in C3H10T1/2 cells co-transfected with a non-targeting or miR433 inhibitor. N=6

Canonical Wnt signaling plays an important role in the regulation of bone homeostasis
and is considered a central positive regulator of osteogenesis

15,60,61.

In adults, Wnt signaling

can avert the differentiation shift of pre-osteoblasts to adipocytes and can inhibit excessive
osteoclastogenesis by regulating osteoblasts

62,63.

Our bioinformatic analysis suggested that

several components of the Wnt signaling pathway could be directly targeted by miR-433, with
RSPO3 (R-spondin 3) (Figure 2.4A) being a particularly strong candidate. R-spondins are LGR
ligands that act as enhancers of Wnt signaling by preventing Wnt receptor degradation 64,65,66.
Co-transfection of the miR-433 inhibitor relieved repression of the Luciferase 3’ UTR construct,
validating Rspo3 as a novel miR-433 target (Figure 2.4G).

Since R-spondins serve to enhance Wnt signaling, we determined whether inhibition of
miR-433 had an impact on canonical Wnt signaling in vitro. To do so, we transiently transfected
cells with a TOPflash vector, to report stimulus-dependent Wnt signaling activity, along with
either a non-targeting or miR-433 inhibitor. The TOPflash reporter contains 7 repeats of a
TCF/LEF binding site driving expression of Luciferase; its transcription is activated upon
stimulation of Wnt signaling. To induce Wnt signaling, transfected cells were treated with 30 or
50 ng/ml Wnt3a. The lower dose of Wnt3a resulted in a similar induction of luciferase activity in
cells treated with either non-targeting or miR-433 inhibitor. In cells transfected with the non22

targeting inhibitor, treatment with the higher dose of Wnt3a did not augment promoter
activity. However, cells treated with miR-433 inhibitor had significantly increased luciferase
activity compared with the low dose or with the non-targeting control. These data indicate that
miR-433 dampens Wnt signaling (Figure 2.4H).

In Vivo Impact of miR-433 Decoy
Many traditional approaches for investigating gene function in vivo center on loss of
function studies through gene inactivation. Given the location of miR-433 in the genome, a
knock-out strategy could compromise RTL1, anti-RTL1, or its neighboring miRNA, miR-127,
presenting potentially confounding variables. To circumvent these issues, we employed a tough
decoy (TuD) inhibitor approach, in which a transgene cassette containing 3 copies of a miR-4333p tough decoy within the 3’ UTR of the reporter gene tdTomato, and driven by the rat Col1a1
promoter (Figure 2.5A). The ability these hairpin-shaped tough decoys to suppress endogenous
miRNA activity has been well characterized and shown to be more effective than the more
traditional “bulged sponge”. While miRNA decoys can decrease the abundance of mature
miRNAs, sequestration of miRNA-mRNA complexes in P-bodies may also provide additional
relief from miRNA targeting 34,67,68.

miR-433 is rhythmically expressed in bone, and using this miR-433TuD mouse model, we
had previously demonstrated that miR-433 dampens circadian rhythm in bone tissue

26.

Further, bone RNA from the 8 week old males had increased levels of Runx2 and osteocalcin
RNA, but the skeletal phenotype of the miR-433 decoy mice was not examined in detail.
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Therefore, we used microCT analysis to assess the microarchitecture of femurs from mice at 8
and 20 weeks of age, representing growing and skeletally mature animals 69. Since our previous
studies were performed in males and preliminary analyses did not suggest an obvious skeletal
phenotype in females (data not shown), all subsequent experiments were carried out in males.
Eight weeks of age is a time of peak trabecular bone volume in B6 mice, and there was no
difference in cortical or trabecular bone parameters between wild-type (WT) and TuD mice (TG)
at this age (Figure 2.5B-E) 69.

From 8 to 20 weeks of age, WT mice displayed a significant increase in cortical thickness,
an effect that trended higher in the miR-433TuD mice (Figure 2.5B). In contrast, as the mice
became older, we observed the expected decrease in trabecular bone volume (20% loss) in the
20 week WT group when compared to 8 weeks (Figure 2.5C). However, this bone volume loss
was attenuated in the 20 week TuD group (7% loss, not significant) (Figure 2.5C). Trabecular
number decreased between 8 and 20 weeks of age in both TuD and WT groups, with no
difference between the genotypes (Figure 2.5D). Trabecular spacing was similarly unaffected by
genotype (data not shown). While there was no significant difference in trabecular thickness
from 8 to 20 weeks in the WT mice, this parameter was increased 17% between 8 and 20 weeks
in TuD mice (Figure 2.5E), an effect that could contribute to attenuation of bone volume loss in
the 20 week TuD mice.
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Figure 2.5. microCT analysis of femurs from 8 and 20 week male wild type (WT) and miR-433TuD
(TG) mice.
(A) Schematic of miR-433 decoy transgene cassette. A 3.6-kb fragment of the rat Col1a1 gene plus the
first intron drive expression of the reporter gene tdTomato and a 3-UTR containing three copies of a
miR-433 tough decoy, a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE),
and bovine growth hormone polyadenylation signal (polyA). (B) Cortical thickness, (C) Bone Volume
Fraction (BV/TV), (D) Trabecular Number, and (E) Trabecular Thickness. µCT reconstructions of (F)
cortical and (G) trabecular bone from 20 week male mice. N = 7-8
Since TuD mice had increased trabecular bone volume at 20 weeks, histomorphometry
was conducted at this age, to examine the impact miR-433 inhibition on cellular parameters
regulating bone homeostasis and their activity. Static histomorphometry did not reveal a
significant difference in osteoblast or osteoclast surface, eroded surface, or osteoblast and
osteoclast numbers between WT and TuD mice (Figure 2.6A-E). However, dynamic
histomorphometry showed a significant increase in mineral apposition rate, bone formation
rate, and mineralizing surface in mice expressing the miR-433 TuD compared to the WT control
(Figure 2.6F-H). Together, these data demonstrate that miR-433 is a negative regulator of bone
formation in vivo.
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WT

TG
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Figure 2.6. Histomorphometric analysis of femurs from 20 week male wild type (WT) and miR-433TuD
mice (TG)
Static histomorphometry (A) Osteoblast number per bone perimeter (N.Ob/B.Pm), (B) Osteoblast surface
(Ob.S/BS), (C) Eroded surface per bone surface (ES/BS), (D) Osteoclast surface per bone surface (Oc.S/BS,
and (E) Osteoclast number per bone perimeter (N.Oc/B.Pm). Dynamic histomorphometry (F) Mineral
Apposition Rate, (G) Bone Formation Rate, and (H) Mineralizing Surface. (I) Representative static
histomorphometry images for WT and TG. Femurs from 20 week male mice. (J) Representative dynamic
histomorphometry images. Femurs from 20 week male mice. Alizarin complexone (red) and calcein
(green) injected 10 and 3 days prior to harvesting, respectively. N= 13-19
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Discussion
In this study, we showed that miR-433-3p is decreased during the osteoblastic
differentiation of primary BMSCs, and confirmed its role as a negative regulator of this process.
Although negative regulators of osteoblastic differentiation often promote adipogenesis,
inhibition of miR-433 did not affect adipocyte differentiation

70

. Whereas miR-433 was

previously shown to target Runx2, a master transcription factor for osteoblastogenesis,
additional miR-433 targets important for the osteoblast lineage were poorly described. Here,
we validated 5 novel miR-433 targets spanning PTH, MAPK, Wnt and glucocorticoid signaling
pathways. Moreover, we demonstrated that miR-433 is a negative regulator of osteoblast
function in vivo, impacting trabecular and cortical bone compartments.

While miR-433-3p decreases during osteogenesis (Figure 2.1C), but we did not define
underlying mechanisms in primary cells. However, like most genes, transcription of miRNA loci
are regulated by epigenetic mechanisms and the binding of regulatory elements by
transcription factors and transcription factor modifiers. Since miRNAs undergo processing steps
in both the nucleus and cytoplasm, levels of mature miRNAs can also be regulated in a posttranscriptional manner

71.

Regarding miR-433, information on the mechanisms regulating its

expression remains fairly limited. Presently, there is little evidence that miR-433-3p is
differentially regulated at the level of pri- or pre-miRNA processing. In contrast, at the
transcriptional level, the miR-433 locus is activated by the orphan nuclear receptor estrogen
related receptor γ (ERRγ, NR3B3), a transcription factor known to inhibit osteogenesis and
decrease of chondrocyte proliferation

25,26,30,72.
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In contrast, miR-433 transcription can be

repressed by small heterodimer partner (SHP, NR0B2), which promotes osteoblast
differentiation
transcription

30,72,73.

42.

An epigenetic program has also been documented to regulate miR-433

For example, the miR-433 promoter contains CpG islands which can be

hypermethylated, and treatment with a DNA methylation inhibitor can induce its expression
42,44,74

.

Expression of a miR-433TuD increased bone formation rate in vivo and osteogenic
marker gene expression in vitro; there are multiple pathways regulating osteoblast function and
considerable crosstalk among these osteogenic pathways. We identified novel miR-433-3p
targets active in PTH, MAPK, Wnt and glucocorticoid signaling pathways, all of which can be
bone anabolic. For example, in the PTH pathway, we established murine Creb1 as a miR-433
target (Figure 2.4B). This leucine zipper transcription factor mediates key signaling downstream
of PTH receptor activation

40,41,75.

In osteoblastic cells, PTH binding to its receptor causes the

activation of adenylate cyclase and production of cAMP. This leads to the activation of protein
kinase A (PKA) and the subsequent phosphorylation of CREB1 76. Once activated, CREB1 binds
to the cAMP response element and triggers a cascade of gene expression that promotes
osteoblast proliferation, commitment to the lineage, and maturation, while inhibiting apoptosis
40,41,77,78,79,80.

Whether miR-433 decoy mice are more sensitive to PTH signaling remains an area

of interest.

Endogenous, physiological glucocorticoid signaling plays a positive role in the acquisition
of bone mass in vivo and promotes the expression of mature osteoblast markers in vitro
Moreover, glucocorticoid receptor signaling is important for normal fracture repair
29

83.

81,82.

We

identified Hsd11b1 as a novel miR-433 target (Figure 2.4C). At the pre-receptor level,
glucocorticoids are regulated locally by Hsd11β isozymes, of which Hsd11β1 is prominently
expressed in osteoblast and osteoclasts, catalyzing the conversion of inactive glucocorticoids to
their active form

45,46,47,84.

It is well known that miRNAs can cause modest changes in the

expression of multiple targets within a single signaling pathway, to mediate significant changes
responsiveness. We had previously established that inhibition of miR-433-3p activity increased
sensitivity to glucocorticoids, while others demonstrated that the glucocorticoid receptor
(Nr3c1) is directly targeted by miR-433

26,85.

That miR-433-3p targets multiple pathway

components critical for promoting glucocorticoid signaling suggests that this miRNA plays an
important role in limiting responsiveness. Indeed, in vivo endogenous glucocorticoids play a
central role in synchronizing peripheral circadian clocks, and in miR-433 decoy mice, the
amplitude of rhythmic gene expression in bone is increased. Increased Hsd11β1 expression due
to decreased miR-433 could amplify levels of active glucocorticoids within cells, and contribute
to the increased sensitivity to glucocorticoid receptor signaling.

In contrast, glucocorticoid excess is one of the leading causes of secondary osteoporosis,
enhancing osteoblast apoptosis and decreasing IGF1 levels, inhibiting bone formation

84,86.

Interestingly, Hsd11β1 is implicated in age-related bone loss, as its activity increases with age
84,87,88.

Moreover, polymorphisms in the Hsd11β1 gene have been associated with osteoporosis

in postmenopausal women 45,89,90,91. Further, Hsd11β1 has also been associated in the efficacy
of glucocorticoid treatment, since the sensitivity to therapeutic glucocorticoids is dependent on
its expression and activity

45,46,92,93.

These translational studies illustrate the potential

importance of regulating local glucocorticoid activity in bone and other tissues.
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Several components in the MAPK signaling pathway, MKK3 and p38α, are directly
targeted by miR-433 (Figure 2.4E, F). MAPKs function as critical signal transducers in response
to a wide spectrum of extracellular stimuli, impacting osteoblast differentiation and function
55,94,95

. The MAPK family contains three well characterized subfamilies: extracellular signal–

regulated kinases (ERKs) which control cell division, c-Jun amino-terminal kinases (JNKs) which
phosphorylate multiple transcription factors, and p38 MAPKs, which activated by TGF family
ligands, inflammatory cytokines and environmental stressors
433 was shown to target the human JNK1 3’ UTR

57.

55,95.

In cardiac fibroblasts, miR-

However, our data indicate that this

regulation was not conserved in mice (Figure 2.4D), unlike the cross-species conservation of
Creb1 targeting by miR-433-3p (Figure 2.4B).

In MAPK signaling, MKK3 is an intermediate member of the phosphor-relay system that
selectively activates p38 MAP kinase, but not p38β or JNK or ERK MAPK family members 96,97.
Within the p38 MAPKs, p38 is noted to be a key regulator of bone homeostasis, regulating
transcription factors needed for osteoblastogenesis, such as Dlx5, Runx2, and Sp7/Osx

97.

Studies using p38 inhibitors in cell lines or primary osteoblasts have shown that the p38
signaling pathway can regulate alkaline phosphatase activity and mineralization in response to
BMP2, TGFβ, PTH, and Wnt ligands

97.

The ability of miR-433 to target both p38 and its

upstream activating kinase, MKK3, suggest that this signaling pathway may play an important
role in the effect of miR-433 on the osteoblast lineage (Figure 2.4E-F).
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Inhibition of miR-433 increased responsiveness to canonical Wnt signaling, and we
verified that RSPO3 is a novel miR-433 target (Figure 2.4G, H). RSPO3 belongs to the R-spondin
family of Wnt agonists, which potentiate canonical Wnt signaling by reducing Wnt receptor
turnover, enhancing subsequent βcatenin stabilization

65,66,98,99.

Although R-spondins vary in

their functional effects with respect to the skeleton, they are expressed in the developing
skeleton, contributing to limb formation

65,66.

During early development, RSPO3 is highly

expressed within the primitive streak, neural tube, brain, limb bud, heart, kidney, and small
intestine 66,100. In mice, Rspo3 disruption during development results in embryonic lethality due
to angiogenic defects in the placenta

65,66,101,102,103.

Rspo2 and Rspo3 are suggested to be

functionally redundant, and loss of Rspo2 in osteoblasts decreases bone formation and
trabecular bone volume 65. While there may be other miR-433 targets within the Wnt pathway
that are yet to be validated, we show that inhibition of miR-433 activity promotes canonical
Wnt signaling, which could contribute to the increased bone formation and bone volume seen
in miR-433 decoy mice.

While we validated miR-433-3p targets in seemingly diverse pathways, these pathways
all have a positive impact on osteoblast differentiation and function, and many have points of
intersection and convergence (Figure 2.7). Moreover, a single miRNA can have tens to hundreds
of mRNA targets. Here, we report on the targets that we identified, not on all miR-433-3p
targets that may be important in osteoblasts. For the most part, miRNAs cause modest changes
in the expression of multiple targets, to mediate a more pronounced effect on cell physiology.
Therefore, it is may be difficult to tie the function of a miRNA to the regulation of single
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pathway or to a single component of a pathway. However, at the risk of over simplifying
complex pathways and limiting the interpretation of our data by considering only known miR433-3p targets, we assembled a working model to illustrate some of the interactions among
miR-433 target pathways. For example, inhibition of miR-433 increases sensitivity to
glucocorticoids and increases the expression of the direct glucocorticoid receptor target gene
DUSP1 (dual specificity protein
phosphatase 1)

26.

One way in

which glucocorticoid receptor
signaling interacts with MAPK
is

by

DUSP1-mediated

dephosphorylation of p38α 104.
Figure 2.7. Simplified working model of miR-433-3p target
interaction pathways. Direct miR-433 targets are in red font.

Moreover, Runx2 is a miR-433

target that can be phosphorylated and activated by p38α, which is also miR-433 target

105.

Transcription mediated by accumulation of nuclear βcatenin has profound effects on
osteoblastic differentiation, as
15,40,41,77,78,79,80,.

does

transcriptional programs

activated by

CREB1

However, bidirectional crosstalk between PTH/cAMP and Wnt signaling

pathways occurs, resulting in cooperative induction of gene transcription

106.

Validation of

additional miR-433 targets is central to a better understanding of its function in osteoblasts and
in other tissues.

Indeed, miR-433 expression is not bone specific; it is broadly although not ubiquitously
expressed. Much of the previous work on miR-433 has involved its role in extra-skeletal
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pathologies. For example, miR-433 is reported to be up-regulated in cases of renal, liver, and
cardiac fibrosis, while down-regulated in cases of gastric carcinoma, Hepatitis B virus-associated
hepatocellular carcinoma, and in visceral adipose tissue from patients with non-alcoholic
steatohepatitis

57,107,108,109,110,111.

miR-433 levels have been linked with tumorigenicity and

neoplastic progression, as either a promoter or suppressor 42,44,74,112. The novel miR-433 targets
validated in this study are likely to have implications in other tissues in which they are coexpressed with miR-433.

With a thorough understanding of key molecular mechanisms regulating osteoblast
differentiation and function, new strategies aimed at increasing bone formation could be
developed. The ability of miRNAs to regulate the differentiation of multipotent cells along an
osteoblastic lineage has become evident, highlighting their potential clinical applications as
orthobiologic agents 113. Not only could miRNA-based therapeutics be used in the management
of skeletal disorders, but they could help treat difficult fractures and accelerate normal
physiological fracture repair 113. While naked nucleic acids are prone to degradation, a number
of viral and non-viral carriers could be utilized to protect, deliver, and increase the transfection
efficiency of miRNA‐based therapeutics 113,114. Although viral vectors result in stable expression
and higher transfection efficiencies, they can be immunogenic, toxic, and have higher
production cost

113,115.

Whilst non-viral vectors are safer and nontoxic, they have lower

transfection efficiencies 113,116.

34

Importantly, there are a number of studies describing biomaterials that can be used as
miRNA‐delivery‐based scaffolds. These biomaterials, including calcium phosphate, peptides,
nanoparticles, lipid‐based or polymeric‐based carriers, and polymeric hydrogels, have the
potential to increase transfection efficiencies without drawbacks associated with viral delivery
113,117,118

. Some of which have already shown preclinical success in treating bone defects

113

.

Overall, we demonstrated that miR-433 is a negative regulator of bone formation, targeting key
bone-anabolic pathways. Local delivery of miR-433 inhibitor could present a strategy for the
management of bone loss disorders and bone defect repair.
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Chapter 3
Review:
microRNAs Regulating TGF and BMP Signaling in the Osteoblast Lineage

Abstract
Osteoblastic differentiation is tightly controlled by a number of signaling pathways
associated with key transcription factors, as well as many microRNAs (miRNAs). miRNAs are
small noncoding RNAs that function in the post-transcriptional regulation of gene expression.
While clinical strategies to combat the reduction in bone density have often centered on
impeding further bone resorption, these strategies neglect to promote bone formation, a
component which is particularly problematic in the aging population. miRNAs could serve to
bridge that gap, as potential therapeutic candidates. Multiple studies have established that
miRNAs can direct osteoprogenitors towards an osteoblastic lineage through modulation of
TGFβ and BMP signaling. miRNAs can target ligands such as the TGFβ isoforms (TGFβ1, TGFβ2,
and TGFβ3) and BMP7, signaling receptors such as TGFβR1 and BMPR2, and signal transducers
such as SMAD1-5. Having a wide understanding of the signaling pathways, differentiation
factors, and the mechanisms necessary for the miRNA-mediated induction of multipotent cells
along an osteoblastic lineage is key for the effective utilization of miRNAs as therapeutic
candidates in the management of bone disorders. Thus, this review aims to showcase miRNAs
regulating to the anabolic activity of bone forming osteoblasts, to illustrate their interaction
with the TGFβ and BMP signaling pathway and effects on bone formation. Therapeutic
implications are also discussed.
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Introduction
Bone is a highly dynamic mineralized tissue that plays two key anatomical roles: metabolic
and mechanical

14,119.

Its metabolic role consists of the ability of bone to regulate serum

electrolytes through the release of mineral from the bone matrix, and energy metabolism via
release of osteocalcin in response to endocrine signals

14,119,120

. In its mechanical role, bone

supports locomotion while protecting soft tissues and major organs

14,16,119.

Bone undergoes

continuous remodeling, which is a complex process necessary for fracture healing and skeletal
adaptation to mechanical use

1,14,15.

During normal remodeling, bone-resorptive osteoclasts,

bone-forming osteoblasts, and mechano-sensing osteocytes orchestrate the remodeling
process by replacing old bone with new, in order to maintain bone homeostasis and structural
integrity

1,14,15.

Aside from intricate cell-to-cell communication, bone remodeling can be

controlled locally by growth factors or cytokines, and systemically through calcitonin and
various endocrine signals – all contributing to bone homeostasis

14,15.

Dysregulation in the

remodeling process could result in an imbalance between bone resorption and formation,
which impacts bone homeostasis and compromises structural integrity, highlighting the need to
study the function and regulation of bone cells and their progenitors 14,15,16.

While osteocytes play a key role in the remodeling process, bone resorption and formation
are carried out by two main cell types: osteoclasts and osteoblasts, respectively

1,14,15.

Osteoclasts are multinucleated cells that originate from mononuclear cells of the hematopoietic
lineage and are driven into an osteoclastic fate primarily by two cytokines, Receptor Activator
of Nuclear Factor Kappa-B Ligand (RANKL) and Macrophage Colony Stimulating Factor (M-CSF)
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14,15,16.

In contrast, osteoblasts originate from multipotent mesenchymal stem cells (MCSs)

1,14,15.

The commitment and differentiation of MSCs into an osteoblastic lineage is tightly

regulated by a number of signaling pathways including the wingless‐type (Wnt), transforming
growth factor-beta (TGFβ), and bone morphogenetic protein (BMP) pathways 1,14,15,16.

Osteoblasts play a pivotal role in sustaining bone microstructure and homeostasis

1,14.

Having the ability to synthesize bone matrix proteins, inadequate osteoblast number or activity
are implicated in the pathophysiology of various bone disorders, including osteoporosis

1,14,15.

Clinical strategies to combat osteoporosis have often centered on impeding further bone
resorption

15.

While this strategy can attenuate bone loss, it neglects to promote bone-

formation, a component which is particularly problematic in the aging population

1,15.

During

aging, there is a gradual decrease of osteoprogenitors, osteoblastic differentiation, and a
reduction of hormone levels such as estrogen and testosterone; this favors bone loss and
increases the risk of fracture

16,121.

Fortunately, microRNA (miRNA)-based therapeutics could

serve to bridge the present gap in bone anabolics.

miRNAs are noncoding RNAs that function in the post-transcriptional regulation of gene
expression

4,5,6,7,8.

miRNA-mediated post-transcriptional regulation is managed primarily

through their direct interaction with mRNAs that contain sequences complementary to the
miRNA, resulting in inhibition of translation and/or enhancement of mRNA degradation

4,5,6,7,8.

These small 21-24 base RNAs are involved in many biological processes such as self-renewal,
proliferation, function, and differentiation

4,5,6,7.

38

Recent studies have established that miRNAs

can direct MCSs towards an osteoblastic lineage through modulation of TGFβ and BMP
signaling – both of which play important regulatory roles in bone formation, bone healing, and
osteoblastogenesis 3. The TGFβ/BMP family is complex; its ligands have both postive and
negative effects on osteoblast commitment, differentiation and activity. Having a wide
understanding of the signaling pathways, differentiation factors, and the mechanisms necessary
for the miRNA mediated induction of multipotent cells along an osteoblastic lineage is key for
the effective utilization of miRNAs as therapeutic candidates in the management of bone
disorders such as osteoporosis.

Thus, this review aims to showcase miRNAs contributing to the regulation of bone forming
osteoblasts through their effects on the TGFβ and BMP pathways, with a focus on ligands,
receptors and SMAD-mediated signaling. While transcriptional and post-transcriptional
mechanisms regulate this pathway, it is also regulated by mechanisms that moderate ligand
availability and activation. One limitation of our review is that we do not consider miRNA
regulation of genes affecting the activity or availabilty of TGFβ family ligands, nor do we address
miRNA regulation of non-canonical signal transduction mechanisms. However, the goal of this
work is to provide a basis for broadly understanding the contribution of miRNAs to the
modulation of TGFβ, BMP and activin signaling in the osteoblast lineage, and the rationale for
potential therapeutic strategies. Therefore, the search strategy for this systematic review was
restricted to validated miRNA targets within the canonical TGFβ and BMP signaling pathways;
miRNA-target interactions based only bioinformatics will not be discussed.
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To set the stage, we will briefly summarize miRNA biogenesis and function, as well as the
TGF and BMP signaling pathways, as an introduction to the players involved.

miRNAs, TGF and BMP Basics
MicroRNAs
Mature miRNAs are derived from primary transcripts (pri‐miRNA) produced principally by
RNA polymerase II (Figure 3.1)

5,6,7,122,123

. While in the nucleus, the pri-miRNA undergoes the

first round of cleavage by a multiprotein microprocessor complex that includes the RNase III
enzyme Drosha and RNA-binding protein DGCR8 (DiGeorge syndrome critical region
8)/Pasha(Partner of Drosha) 5,6,7,8,19,122,123. This initial cleavage results in a precursor miRNA (premiRNA) which is subsequently transported to cytoplasm by Exportin-5 and Ran-GTP

1,7,8,122,123.

Once in the cytoplasm, the 70-80 nucleotide pre-miRNA is further cleaved by an RNase III
enzyme, Dicer, to produce a mature miRNA duplex

5,6,7,8,19,122,123

. This miRNA duplex is then

unwound, isolating the mature singled-stranded miRNA (guiding strand) from its
complementary passenger strand, which is degraded

5,6,7,8,19,122,123.

The remaining single-

stranded miRNA “guiding strand” is loaded onto an RNA-induced silencing complex (RISC) which
contains Dicer, one of the Argonaute family of proteins (a central component and key player),
and additional RNA-binding proteins 5,6,7,8,19,122,123. As part of this complex, the miRNA facilitates
the sequence-specific recruitment of RISC to complementary regions within the target mRNA
5,7,8,122,123.

With this sequence-specific interaction, miRNAs can regulate gene expression by

destabilizing mRNAs through cleavage, or deadenylation of the target mRNAs or through the
inhibition of protein translation 3,5,7, 19,122,123,124.
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Figure 3.1 miRNA Biogenesis
miRNAs are transcribed by RNA-polymerase II into primary transcripts called pri-mRNA. The pri-miRNA is
cleaved into pre-miRNA by Drosha and its RNA-binding partner DGCR8. The pre-miRNA is subsequently
exported by Exportin-5 out of the nucleus, where it is further sliced by another RNase III enzyme, Dicer, to
result in a miRNA duplex. The miRNA duplex is unwound and the mature single strand is incorporated into
the RISC complex. Depending on the degree of complementary to the target mRNAs, once in the RISC
complex, the mature miRNA can lead to translational repression, mRNA deadenylation, and/or mRNA
degradation.

TGF Superfamily Signaling
The TGFβ superfamily is composed of over 30 members including TGFβs, BMPs, growth
differentiation factors (GDFs), and activins
in the regulation of bone homeostasis

125,126.

9,125,127.

Members of TGFβ superfamily play key roles

Additionally, they can regulate skeletal muscle

repair, cellular immune responses, and even prolong cell survival through the suppression of
programmed cell death in different cell types
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3,9,125,127,128.

There are 3 TGFβ isoforms in

mammals (TGFβI, TGFβII, and TGFβIII), all of which are implicated in the function and
metabolism of bone cells 9. TGFβ has also been documented to exert a biphasic effect on
osteoblastic differentiation by promoting activation, proliferation, and early commitment of
pre-osteoblasts at an early state, while impeding terminal osteoblast differentiation at later
stages, especially during mineralization 10,11.

BMPs are the largest subdivision of the TGFβ superfamily, and are composed of nearly 30
different human proteins

126,129,130.

Due to the differences among members of the BMP

subdivision, in terms of mechanics and downstream cellular effects, the term BMP is restricted
to molecules that elicit activation of the canonical BMP signaling pathway, limiting the list to
roughly 12 BMP ligands in humans

126.

BMPs play a pivotal role in bone formation during

development and they promote the restoration of critical-size bone defects
BMPs display strong osteogenic capacities

13.

12.

A number of

For example, addition of BMP2 can increase

osteocalcin and bone formation, whereas a severe impairment of osteogenesis results from the
loss of both BMP2 and 4

131,132.

BMP7 is also osteogenic, mediating an increase in the

expression of osteoblastic markers and mineralization in vitro 132,133,134.
TGFβ superfamily ligands can initiate signaling cascades via both SMAD-dependent
(canonical pathway; Figure 3.2) and a SMAD-independent (non-canonical) pathways 1,3,135,136,137.
In canonical signaling, SMAD family members facilitate signal transduction from the ligandactivated receptors, translocating to the nucleus to regulate expression of downstream target
genes 126,135,136. The name “SMAD” references its similarity to the SMA protein of C. elegans and
the MAD (Mothers Against Decapentaplegic) protein in Drosophila 135.
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Figure 3.2 TGF and BMP Signaling
Canonical signaling is initiated upon ligand binding to pairs of membrane receptor serine/threonine
kinases (receptor types I and II), promoting the formation of a hetero-tetrameric receptor complex.
Within this complex, the type 2 receptor phosphorylates and activates the type 1 receptor, which
recruits and phosphorylates R-SMADs. Phosphorylated R-SMADs form heterooligomer complexes
with SMAD4 for transcriptional regulation. This complex translocates to the nucleus where it interacts
with different DNA-binding cofactors that confer target gene selectivity and regulation.

There are three types of SMADs in mammals: receptor‐regulated SMADs (R‐SMADs), common‐
partner or comediator SMADs (Co‐SMADs), and inhibitory SMADs (I‐SMADs) 135,136,138. R-SMADS
are the five SMADs that act as substrates for the TGFβ family of receptors (SMADs 1,2,3,5, and
8)

135,136,138.

SMAD4, the only Co-SMAD, serves as a common partner for R-SMADs

135,136,138.

Lastly, SMAD6 and SMAD7 are I-SMADs, which interfere with the SMAD-receptor or SMADSMAD interactions and function in the negative feedback loop 135,136,138.
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Activation of canonical signaling is initiated with TGFβ family ligands binding to a
heterotetrameric receptor complex in the cell membrane

124,139.

This receptor complex is

comprised of two type 1 receptors and two type 2 receptors, which are transmembrane dual
specificity kinases 140. Upon binding of ligand, the type 2 receptor phosphorylates and activates
the type 1 receptor, which recruits and phosphorylates R-SMADs: SMAD2 and 3 for TGF
receptors and ligands, and R-SMADs 1,5 and 8 for BMP receptors and ligands

124,139.

This

phosphorylation renders the R-SMADs active and able to form a heterooligomer complex with
the ubiquitous SMAD4 124,126,129,130,135,136,138,139. The formation of this complex promotes nuclear
translocation 124,135,136,138,139. Once in the nucleus, the R-SMAD/SMAD4 complex binds to DNA in
cooperation with other transcription factors and cofactors to induce or repress gene
transcription 124,135,136,140,141.

miRNA Regulation of TGF Family Ligands
One manner in which miRNAs exert their regulatory role is by directly targeting the TGFβ
superfamily ligands (Table 3.1). miR-422a, for example, was shown to the target TGFβ2 3′ UTR
in human osteosarcoma cells, which display decreased levels of miR-422a and enhanced
expression of TGF2 142. miR-675, encoded within the paternally imprinted lncRNA H19, directly
targets human TGF1143. Interestingly, miR-675-5p targets the TGF1 5’ UTR, whereas the -3p
isoform targets within the coding region
Runx2 and osteocalcin RNAs

143.

143.

Inhibition of miR-675 in human MSCs decreased

TGF3, on the other hand, is targeted by miR-140-3p

144.

The

expression of miR-140 is reduced in osteoblastic cells over expressing Wnt3a, suggesting a
possible mechanism contributing to crosstalk between these two signaling pathways 144. TGF3
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is also targeted by miR-29b, a pro-osteogenic miRNA that increases during osteoblastic
differentiation 145.
Table 3.1 miRNA Regulation of Ligands
miRNA
Target
Cell Type
miR-422a
miR-675-3p
and -5p
miR-140-3p

miR-29b

Similar to TGFβ, BMP2 can also be
Reference

TGFβ2

Osteosarcoma
cells

142

TGF1

Human
mesenchymal
stem cells

143

MC3T3-E1

144

TGF3

TGF3

miR-17-5p

BMP2

miR-106a

BMP2

miR-106-5p

BMP2

miR-542-3p

BMP7

Human aortic
valve interstitial
cells
Human
adipose-derived
stem cells
Human
adipose-derived
stem cells
Human
placental stem
cells
Mouse calvarial
osteoblasts

directly targeted by miRNAs, such as
miR-17-5p and miR-106a, to inhibit
146.

osteogenesis

In

this

study,

overexpression of miR-17-5p and
miR-106a in human adipose-derived
145

mesenchymal stem cells (hADSCs)
resulted

146

146

in

downregulation

of

endogenous BMP2, suppression of
osteogenesis, and a decrease in the
expression of osteogenic genes such

147

148

as

Runx2,

Osterix/SP7,

phosphatase,
Osteocalcin

146.

alkaline

Osteopontin,

and

Interestingly, while

overexpression of miR-17-5p and miR-106a inhibits osteogenesis, it promotes adipogenesis,
with a significant increase in oil red O staining lipid droplets and adipogenic gene expression
(PPAR and C/EBPα)

146.

These data suggest a role for miRNAs in balancing commitment of a

common progenitor to either an osteoblastic or adipogenic fate. Further, miR-106b-5p can also
target BMP2 (human placental stem cells). In a murine model of glucocorticoid-induced
osteopenia, injection of lentivirus expressing a miR-106b inhibitor attenuated bone loss and
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increased BMP2 mRNA in femurs. These data indicate that the targeting of BMP2 by miR-106b5p is conserved across species, and provide proof-of-concept for targeting miR-106 to prevent
bone loss 147.

BMP7 is also osteogenic, and this BMP is targeted by miR-542-3p. Calvarial osteoblasts
transfected with miR-542 inhibitor had increased osteoblastic marker gene expression, and
mice injected with miR-542-3p inhibitor displayed increased trabecular bone volume.
Importantly, miR-542 inhibitor partially attenuated bone loss associated with ovariectomy, as
well as deficits in bone mechanical properties 148.

miRNA Regulation of Signaling Receptors
Aside from targeting ligands, miRNAs can regulate osteoblastic differentiation by targeting
type I and type II receptors needed to transduce signaling from TGFβ family ligands (Table 3.2).
For example, miR-181 was shown to target TGFβRI/ALK-5

149.

Overexpression of miR-181 in

MC3T3 and C2C12 mouse mesenchymal cells decreased TGFR1 protein levels and upregulated
osteoblastic marker gene expression, as well as alkaline phosphatase activity 149. Since TGFβ can
inhibit terminal osteoblastic differentiation, miR-181-mediated downregulation of TGFβRI
enhanced osteoblastic differentiation in these cell types

149.

In addition, TGFR1 can also be

targeted by miR-140-5p 150. Interestingly, both miR-181 and miR-141-5p are induced and highly
expressed during a femoral fracture repair model in rats. However, a correlation between their
expression and TGF signaling was not addressed in this fracture model 158.
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Table 3.2. miRNA Regulation of Receptors
miRNA
Target
Cell Type

Reference

miR-181

TGFβRI/
ALK-5

MC3T3 and C2C12

149

miR-140-5p

TGFR1

ST2

150

TGFR2

Palatal
mesenchymal cells

151

TGFR2

Human amnionic
membranederived
mesenchymal cells

152

TGFR2 can be targeted by miR17 and miR-20a, which share the
same seed binding region, and are
expressed from the miR-17~92

miR-17 and
miR-20a
miR-204-5p

cluster

TGF signaling plays a

key role in palatal mesenchyme
development,

miR-210

AcvR1b/
ALK-4

ST2

153

miR-208-3p

AcvR1/
ALK-2

MC3T3-E1

154

AcvR-2a

Human
mesenchymal
stem cells

155

miR-16

151.

and

ablation

of

TGFR2 in craniofacial neural crest
results in cleft palate

159.

The

expression of miR-17 and -20a are
decreased from E12 to E14 in

miR-1187

BMPR2

Mouse calvarial
osteoblasts

156

miR-494

BMPR2

C2C12

157

mouse

embryonic

development,

and control of TGFR2 levels by
miRNAs may be important for

normal craniofacial development

159.

Similarly, TGFR2 can be targeted by miR-204-5p, a

miRNA decreased during the osteogenic differentiation of human amnionic membrane-derived
mesenchymal cells 152.

As discussed previously, activin receptor signaling negatively regulates osteoblastic
differentiation

160.

The type I activin receptor, AcvR1b/ALK-4 can be targeted by miR-210 to

promote osteoblast differentiation

153.

Expression of miR-210 is induced by BMP4, and when
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overexpressed in bone marrow stromal cell line ST2, miR-210 induced expression of osteogenic
gene markers genes (Osterix, alkaline phosphatase, and Osteocalcin)

153.

The type I receptor

AcvR1/ALK2 is required for BMP7 signaling. This receptor is targeted by miR-208a-3p, a miRNA
that is highly induced in mechanical unloading, a circumstance known to produce bone loss as
well as a decrease in AcvR1 expression. In mice subjected to hind limb unloading, injection with
miR-208a-3p inhibitor partially rescued bone loss

154.

Further, miR-16 can negatively regulate

osteoblastic differentiation by direct targeting of the type II activin receptor, AcvR2a. In this
study, the authors utilized a miRNA delivery system containing nanohydroxyapatite (nHA)
particles and collagen-nHA scaffolds to deliver antagomiR-16, which increased the relative
levels of Runx2 and Osteocalcin, as well as calcium deposition 155.

BMPR2 is targeted by several miRNAs, including mechanosensitive miR-494. This miRNA is
induced in cultured mesenchymal cells subjected to simulated microgravity, as well as in bone
from mice experiencing hindlimb suspension. Inhibition of miR-494 augmented BMP2-induced
osteoblastic gene expression in vitro 157. BMPR2 is also targeted by miR-1187. Expression of this
miRNA is decreased in BMP2-treated mouse calvarial osteoblasts in vitro, suggesting a feedforward loop to promote BMP signaling. Importantly, injection of mice with miR-1187 inhibitor
decreased trabecular bone loss caused by ovariectomy 156.
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Table 3.3. miRNA Regulation of SMADs
miRNA
Target
Cell Type

miRNA Regulation of SMADs
Reference
miRNAs

miR-100

SMAD1

can

also

regulate

161

MC3T3-E1

osteoblast differentiation and bone
miR-30
Family

SMAD1

MC3T3-E1

162

miR-10b

SMAD2

Human adiposederived stem
cells

165

miR-19a-3p

SMAD2
SMAD4

Human prostate
cancer cell lines

166

SMAD3

MC3T3-E1

163

SMAD3

Human bone
marrow stromal
cells

164

C3H10T1/2

167

miR-23b
miR-221-5p

formation through direct targeting
of

signal

transducing

receptor

SMADs (Table 3.3). For example,
SMAD1

mediates

signaling

downstream of the BMP family
ligands, and has been shown to be
targeted by several

miR‐144‐3p

SMAD4

miRNAs, including miR‐100

161.

miR-106-5p

SMAD5

C2C12

168

miR-17-5p

SMAD5

MC3T3-E1

168

decreased

miR-155

SMAD5

MC3T3-E1

169

alkaline phosphatase activity (a

miR-135

SMAD5

C2C12

170

miR-21-5p

SMAD5

Human
periodontal
ligament cells

171

miR-16

SMAD5

hMSCs

155

Overexpression
SMAD1

of

miR-100
levels

and

marker of osteogenesis) in the
MC3T3-E1 pre-osteoblastic cell line,
suggesting that miR-100 acts as an
endogenous negative regulator of
differentiation 161. The miR-30 family
miR-21

SMAD7

MC3T3-E1

172,173

also targets SMAD1, blunting BMP2miR‐590‐5p

SMAD7

174

MG63

induced osteoblastic differentiation

162.
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As discussed earlier, TGF signaling can have either pro- or anti-osteogenic effects,
depending on cellular context; therefore miRNAs that directly target R-SMADs 2 and 3 may
induce or inhibit osteoblastogenesis. For example, miR-23b was shown to target SMAD3 in
MC3T3-E1 cells. The down regulation of miR-23b in cells treated with the inflammatory
stimulus LPS was associated with increased SMAD3 and decreased osteoblastic differentiation
163.

In contrast, SMAD3 targeting by miR-221-5p in human bone marrow stromal cells was

shown to have an inhibitory effect on osteoblastic differentiation 164. The differential impact of
SMAD3 inhibition on osteoblast differentiation in these two studies is likely related to
differences in the cell systems used, as well as likely effects of the miRNA inhibitors on targets
other than SMAD3.

There seem to be fewer studies on miRNAs targeting SMAD2 in the osteoblastic lineage.
However, miR-10b was suggested to promote osteoblastogenesis at the expense of
adipogenesis, in part by its ability to target SMAD2 165. miR-19-3p was shown to target SMAD2
and SMAD4 in human prostate cancer cell lines

166.

Since miR-19a is also expressed in

osteoblasts, the miR-19/SMAD2/4 targeting interaction validated in prostate cancer is likely
relevant for the osteoblast lineage as well

175.

Similarly, miR-144-3p can regulate osteogenic

differentiation and proliferation of MSCs by direct targeting of SMAD4

167.

In this study,

overexpression of miR-144-3p was shown to blunt osteogenic differentiation and inhibition of
miR-144-3p reversed this process 167.
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A number of studies established the suppression of osteogenic differentiation by miRNA
targeting of SMAD5. For example, miR-106b-5p and miR-17-5p, which have the same seed
binding region, target SMAD5 in mouse mesenchymal cells. Expression of these miRNAs is
repressed during BMP2-induced osteogenesis in both C2C12 and MC3T3-E1 cells, suggesting a
feed forward loop to promote osteoblastic differentiation. Further, delivery of antagomiR for
either miR-106b-5p or miR-17-5p could partially attenuate bone loss in ovariectomized mice
and increased SMAD5 RNA in bone

168.

miR-155 also inhibited osteogenic differentiation by

downregulating the translation of SMAD5 in MC3T3-E1 cells 169. In human periodontal ligament
stem cells, miR-21-5p was shown to target SMAD5, contributing to the ability of this miRNA to
inhibit osteoblastic differentiation. In this study, bioinformatics suggested that other members
of the BMP signaling pathway could be potential miR-21-5p targets, but only SMAD5 was
validated 171. Further, miR-16 negatively regulate osteoblastic differentiation by direct targeting
of SMAD5. In this study, a miRNA delivery system consisting of nanohydroxyapatite (nHA)
particles and collagen-nHA scaffolds was used to deliver antagomiR-16, which increased the
relative levels of Runx2, Osteocalcin, and calcium deposition 155. Lastly, the expression of miR135a decreases in C2C12 cells treated with BMP2, and this miRNA targets SMAD5, contributing
to the inhibitory effect of miR-135a on osteogenesis 170.

On the other hand, targeting of inhibitory SMADs has been shown to promote osteogenic
differentiation

3,172,173,174.

For example, downregulation of SMAD7 by miR-21a-5p promotes

osteogenic differentiation and increases matrix mineralization in MC3T3-E1 cells

172,173.

It is

intriguing that this miRNA also targets SMAD5, which transduces signaling downstream of
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BMPR stimulation. The ability of one miRNA to target both positive and negative regulators in
the same signaling pathway is not uncommon and supports the concept that miRNAs function
to fine tune the amplitude and tempo of signaling. miR‐590‐5p can also promote osteogenic
differentiation and target SMAD7

174.

This miRNA is increased during the osteoblastic

differentiation of both human and mouse MSCs. In this study, transfection of a human
osteosarcoma cell line with a miR-590-5p mimic resulted in increased Runx2 protein and
decreased SMAD7, as well as increased expression of osteoblast differentiation markers and
calcium deposition

174.

These data suggest that miR-590-5p attenuates SMAD7-mediated

inhibition of osteoblast differentiation 174.

Translational Implications
A thorough understanding of key molecular mechanisms regulating osteoblast
differentiation and function is crucial for the development of new strategies aimed at increasing
bone formation. miRNAs are estimated to post-transcriptionally regulate more than 60% of
mammalian genes

113.

In the bone field, studies on miRNA-mediated gene regulation are

increasing, defining their functional contribution to the mammalian skeletal system through the
regulation of signaling pathways important for bone metabolism. This work highlights the
potential clinical applications of miRNAs as orthobiologic agents 113. In particular, since delivery
of BMP2 is presently used to promote bone formation in vivo, miRNAs regulating the BMP
signaling pathway are of interest. Therefore, studies that identify novel miRNA-target
interactions and those examining in vivo models of miRNA knock down or over expression are
critical for providing rationale and proof-of-concept for miRNA-based therapeutics in the
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management of skeletal disorders. Indeed, approximately 16 million bone fractures occur in the
United States annually, of which 10-15% display either delayed healing or non-unions, which
increase patient morbidity and mortality. Local delivery of miRNA-based therapeutics could
help treat difficult fractures and accelerate normal physiological fracture repair 113.

While naked miRNAs are prone to degradation, a number of viral and non-viral carriers
could be utilized to protect, deliver, and increase the efficiency of miRNA‐based therapeutics
113,114.

An example of this strategy is the single injection of miRNA expressing plasmids enclosed

in microbubbles over a fracture callus, followed by ultrasound to break the microbubbles and
deliver the plasmid 176. Although viral vector-mediated delivery can result in stable and higher
levels of transgene expression, they have drawbacks in that they can be immunogenic, toxic,
and have higher production cost 113,115.

Despite the fact that non-viral vectors or small RNAs are safer and nontoxic, they have
lower transfection efficiencies

113,116.

However, a number of studies describe biomaterials that

can be used as miRNA‐delivery‐based scaffolds to increase transfection efficiencies. These
include materials such as chitosan, calcium phosphate, peptides, nanoparticles, lipid‐based or
polymeric‐based carriers, and polymeric hydrogels

113,117,118.

Some of materials have already

shown preclinical success in treating bone defects 113.

There are a number of strategies for chemically stabilizing small RNA inhibitors
(antagomiRs) or miRNA mimics (agomiRs) for delivery to cells or whole animals, and some of
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these modified small RNAs are in phase 1 or 2 clinical trials for diseases including fibrosis and
cancer

34,177,178,179.

In regard to bone, some investigators have demonstrated the efficacy of

periosteal injections of miRNA-based therapeutics at fracture sites in rodent models. These
resulted in an acceleration of repair and decrease of callus width, as well as an increase in
osteogenic marker genes and increased callus bone mineral density, respectively

113,176,180

.

microRNA sponges expressed in cells have also been used as competitive inhibitors of
endogenous microRNAs

34,181.

When transiently transfected into cells, vectors that encode for

these sponges (which contain strong promoters and multiple tandem binding sites for a miRNA
of interest) can inhibit miRNA function efficiently, although its effects are not sustained 34,181. In
order to induce long-term suppression of miRNA, a decoy RNA system using lentiviral vectors
containing RNA cassettes driven by RNA polymerase III could be utilized

34.

Through additional

optimization of the decoy’s secondary structures and the miRNA-binding site, this highly potent
miRNA inhibitory system could be used for well over 1 month 34.

Characterizing the function of individual miRNAs in skeletal tissue and their subsequent
testing in pre-clinical models advances the utility/feasibility of miRNA-based therapeutics in the
management of skeletal disorders and, in particular, bone defect repair. Presently, bone grafts
are a predominant method used to treat bone defects, delayed unions or non-unions

182.

Integration of grafts with host bone can be challenging, hence improving the osteointegration
of these grafts is of utmost importance. To tackle this issue, bone grafting procedures have
been shifting to include addition of various biological growth factors, such as BMPs, and have
exhibited good bone formation and osteointegration 182. While use of growth factors presents a
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clinical improvement, further applications are limited due to concerns regarding high costs,
supraphysiological doses, and side effects

182.

To circumvent these issues, a more complete

understanding of miRNAs affecting the BMP signaling pathway is of considerable interest and
could lead to the development of improved therapies for bone regeneration

183.

It is possible

that localized delivery of miRNA-based therapeutics can modulate the BMP signaling pathway
to promote bone formation and/or decrease the amount of exogenous BMP used in the
patient. Additionally, the synthesis of small RNAs could be less expensive than that of
proteins/peptides.
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Supplemental Data

Supplemental Table 1. Sequence for Tough Decoys. miR-433 and C. elegans miR-67 binding
sites are underlined in miR-433 TuD and non-targeting TuD respectively. For the transgenic
mouse, three miR-433 TuD were assembled (underlined) and DNA from the coding region of
the C. elegans Cut3 gene (denoted by lower case letters) was used as spacer between the
miR-433 decoy copies.
Construct
Sequence
miR-433
Decoy

GACGGCGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAA
GTATTCTGGTCACAGAATACAACACACCGAGGAGCCTAACCATCATGATCA
AGATGATCCTAGCGCCGTCC GA

Nontargeting
Decoy

GATATCGACGGCGCTAGGATCATCAACTCTACTCTTTCTAGAGCTGAGGTTGT
GACAAGTATTCTGGTCACAGAATACAACTCTACTCTTTCTAGAGCTGAGGTTGT
GACAAGATGATCCTAG CGCCGTCATCGAT

miR-433
Decoy
Cassette for
Transgenic
Mouse

GACGGCGCTAGGATCATCAACACACCGAGGAGCCTAACCATCATGATCAAGTAT
TCTGGTCACAGAATACAACACACCGAGGAGCCTAACCATCATGATCAAGATGATC
CTAGCGCCGTCCaggttgttccaatgccaatctgtaaatacgagattcttaacgggttcaattcgcaact
attggacaacaacacaaatggaccGACGGCGCTAGGATCATCAACACACCGAGGAGCCTA
ACCATCATGATCAAGTATTCTGGTCACAGAATACAACACACCGAGGAGCCTAACCAT
CATGATCAAGATGATCCTAGCGCCGTCGGCCGGCCGTCGACCTGCAGTtttgaagaaga
gatccgctccagtaatggagaatattcttgatgtGACGGCGCTAGGATCATCAACACACCGAGGA
GCCTAACCATCATGATCAAGTATTCTGGTCACAGAATACAACACACCGAGGAGCCTA
ACCATCATGATCAAGATGATCCTAGCGCCGTCCGA
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Supplemental Table 2. PCR Cloning Primers. GenBank reference numbers for the Mus musculus genes of
interests are included. Restriction sites are underlined.
Restriction
Gene
FW Primer (3’-5’)
RV Primer (3’-5-)
Enzymes
MKK3
MitogenFW: SpeI
activated Protein atgctaACTAGTGGACTGGCCCAGGAC gcgcgcAAGCTTAAAACAGCAATAGGT
TCCTGCCC
RV: HindIII
Kinase Kinase 3 CCCACTGG
(NM_008928.5)
p38alpha
Mitogenactivated Protein
Kinase 14
(NM_001168514.
1)
JNK1
Mitogenactivated Protein
Kinase 8
(NM_016700.4)
Hsd11β1
hydroxysteroid
11-beta
dehydrogenase 1
(NM_008288.2)
RSPO3
R-spondin 3
(NM_028351.3)
CREB
cAMP responsive
element binding
protein 1
(NM_133828.2)
Proximal site
CREB
cAMP responsive
element binding
protein 1
(NM_133828.2)
Distal site

cgacgcgtACTAGTGCACCTGGTTTCTG
TTCTGTCTATC

GccggcACGCGTTTAACCAGTGGTATT
ATCTGACATCC

FW: SpeI
RV: MluI

atcgatcgACTAGTCCAGCTCCCACTTG
CCAGCAATCA

agtagatACGCGTAAATGCCGTGCAGG
CTAGCGCTGA

FW: SpeI
RV: MluI

tatataACTAGTGAACTCCTGAGCCCTG
GTGAGTGG

CcccccAAGCTTATATTTAATGTTACAT
TAGTTATC

FW: SpeI
RV: HindIII

tatatGAGCTCAGGGTCCTGCGAGGTT
ACTGTAGAC

gagggAAGCTTGATACACCTTGTTAGA
AAGTAGTATC

FW: SacI
RV: HindIII

attttACTAGTTTGGGATTTAAGTTCTCT
CCTGTTAC

cacagtgtaaatgcagcagtggactaggta

FW: SpeI
RV: HindIII

atataACTAGTCAGCTGACCCTTTTGTC
TTCCTCCT
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tgatctttcttccctactgattttttcaac

FW: SpeI
RV: HindIII
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